Who's who

3 Houston innovators to know this week

Meet this week's Houston innovators to know. Courtesy photos

It's safe to say most Houstonians have been glued to their TVs watching the Houston Astros in the World Series, but the city never sleeps on innovation news. And, one of this week's who's who of Houston innovation even has a World Series-worthy technology.

Here are this week's Houston innovators to know.

Patrick Lewis, co-founder of BBL Ventures

Patrick Lewis co-founded BBL Ventures that helps connect energy companies to startups that have innovative technology solutions for their pain points. Courtesy of Patrick Lewis

On last week's episode of the Houston Innovators Podcast, Patrick Lewis, co-founder of BBL Ventures, with his 25-year career in tech investing, took the mic to discuss Houston innovation, the energy tech industry, and BBL's progress with matchmaking big corporations and the startups that can help them stay competitive.

"At our core, we're an investment firm, but our mission statement is to be the innovation partner for the energy and natural resources industry," Lewis says on the podcast. Read more.

Brian DiPaolo, the chief technology officer of Accudata Systems

Through a partnership between two Houston companies, installing breast cancer screening technology is easier than ever. Courtesy of Acudata Systems

It's National Breast Cancer Awareness Month, and the demand for access to detection facilities is rising. Two Houston companies joined forces to help optimize detection.

Brian DiPaolo, the chief technology officer of Accudata Systems, along with Solis Mammography announced a new partnership with the creation of Center-in-a-Box, a technology solution that supports the rapid deployment of breast screening and diagnostic service. Combining IT design, engineering, equipment installation, and go-live support into one full-service package, Center-in-a-Box is forecasted to grow Solis by approximately 30 to 60 new mammography centers within the next 24 months.

"What differentiates Accudata is the services we provide," says DiPaolo. "From procurement and project management to design, installation, and ongoing support, Accudata is a one-stop shop for turning up a new site quickly." Read more.

Ben Fairchild, founder of Fairchild Sports Performance

Ben Fairchild is in the business of keeping athletes — from professionals to amateurs — in top shape. Courtesy of FSP

Sports technology is a burgeoning business and Ben Fairchild, founder of Fairchild Sports Performance, sees the value for its clients. Fairchild has created an app that allows users to stay in shape and access training from anywhere. This has been especially helpful for Fairchild's MLB athletes, which includes World Series athletes George Springer, right fielder for the Houston Astros, and Anthony Rendon, third baseman for the Washington Nationals,

"The FSP app is for anybody who has a body," Fairchild says. "We want to find solutions for long-term health and fitness challenges for people of all walks of life." Read more.

Trending News

Building Houston

 
 

InformAI has three AI-based products geared at improving health care. Photo via Getty Images

In Houston, we’re lucky to have top-tier doctors in the Texas Medical Center, ready to treat us with the newest technology. But what about our family members who have to rely on rural hospitals? Thanks to one Houston company, doctors in smaller community hospitals may soon have new tools at their disposal that could improve outcomes for patients around the world.

Since InnovationMap last caught up with Jim Havelka, CEO of InformAI, two years ago, that hope has come far closer to a reality. InformAI is a VC-backed digital health company. Part of JLABS @ TMC innovation facilities, the company uses artificial intelligence to develop both diagnostic tools and clinical outcome predictors. And two of the company’s products will undergo FDA regulatory testing this year.

SinusAI, which helps to detect sinus-related diseases in CT scans, received its CE Mark — the European equivalent of FDA approval — last year and is being sold across the Atlantic today, says Havelka. He adds that in the United States alone, there are roughly 700,000 sinus surgeries that the product is positioned to support.

Another product, RadOnc-AI, is designed to help doctors prescribe radiation dose plans for head and neck cancers.

“Ideally the perfect plan would be to provide radiation to the tumor and nothing around it,” says Havelka. “We’ve built a product, RadOnc-AI, which autogenerates the dose treatment plan based on medical images of that patient.”

It can be an hours-long process for doctors to figure out the path and dose of radiation themselves, but the new product “can build that initial pass in about five minutes,” Havelka says.

That in itself is an exciting development, but because this technology was developed using the expertise of some of the world’s top oncologists, “the first pass plan is in line with what [patients would] get at tier-one institutions,” explains Havelka. This creates “tremendous equity” among patients who can afford to travel to major facilities and those that can’t.

To that end, RadOnc-AI was recently awarded a $1.55 million grant from the Cancer Prevention and Research Institute of Texas, or CPRIT, a state agency that funds cancer research. The Radiological Society of North America announced late last year that InformAI was named an Aunt Minnie Best of Radiology Finalist.

“It’s quite prestigious for our company,” says Havelka. Other recent laurels include InformAI being named one of the 10 most promising companies by the Texas Life Science Forum in November.

And InformAI is only gaining steam. A third product is earlier in its stage of development. TransplantAI will optimize donor organ and patient recipient matches.

“A lot of organs are harvested and discarded,” Havelka says.

His AI product has been trained on a million donor transplants to help determine who is the best recipient for an organ. It even takes urgency into account, based on a patient’s expected mortality within 90 days. The product is currently a fully functional prototype and will soon move through its initial regulatory clearances.

The company — currently backed by three VC funds, including DEFTA Partners, Delight Ventures, and Joyance Partners — is planning to do another seed round in Q2 of 2023.

“We’ve been able to get recognized for digital health products that can be taken to market globally,” says Havelka.

But what he says he’s most excited about is the social impact of his products. With more money raised, InformAI will be able to speed up development of additional products, including expanding the cancers that the company will be targeting. And with that, more and more patients will one day be treated with the highest level of care.

Trending News